In particular, immunecheckpoint inhibition (ICI) strategies targeting the programmed cell death protein 1 (PD-1), programmed cell death protein ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are approved for a large number of different cancers [1]. This evidence concerns the gene CTLA4 and cancer.